Drug Profile
Research programme: Translation regulators - Effector Therapeutics
Alternative Names: eIF-4E; Selective translation inhibitorLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Effector Therapeutics
- Developer eFFECTOR Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Eukaryotic initiation factor 4E inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Solid-tumours in USA
- 28 Apr 2019 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 05 Dec 2018 eFFECTOR Therapeutics plans preclinical trial of eIF4E trial for solid tumour and haematological malignancies in 2019